SCHEMBL6276231

SCHEMBL6276231

COC(=O)c1ccccc1-c1ccc(OC)cc1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A3 Q01959 4/20 0.71
SLC6A4 P31645 3/20 0.71
KDM4E B2RXH2 2/20 0.71
CYP1A2 P05177 1/20 0.71
CYP2D6 P10635 1/20 0.71
CYP2C9 P11712 1/20 0.71
CYP2C19 P33261 1/20 0.71
SLC6A2 P23975 1/20 0.67
POLB P06746 1/20 0.61
GAA P10253 1/20 0.61
GABRG2 P18507 2/20 0.56
GABRB3 P28472 2/20 0.56
GABRA3 P34903 2/20 0.56
GABRA1 P14867 1/20 0.56
GABRA5 P31644 1/20 0.56
GABRA2 P47869 1/20 0.56
SMN1; SMN2 Q16637 1/20 0.54
HDAC4 P56524 1/20 0.54
HDAC2 Q92769 1/20 0.54
HDAC8 Q9BY41 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1639148 0.87 SLC6A3 (0.67) SLC6A3SLC6A4KDM4ECYP1A2CYP2D6
SCHEMBL29011848 0.86 GAA (0.60) SLC6A3SLC6A4KDM4ECYP1A2CYP2D6
SCHEMBL31318316 0.86 SLC6A3 (0.78) SLC6A3SLC6A4KDM4ECYP1A2CYP2D6
SCHEMBL30045516 0.86 GAA (0.60) SLC6A3SLC6A4KDM4ECYP1A2CYP2D6
SCHEMBL27843639 0.85 SLC6A3 (0.74) SLC6A3SLC6A4KDM4ESLC6A2POLB
SCHEMBL1775832 0.85 SLC6A3 (0.74) SLC6A3SLC6A4KDM4ESLC6A2POLB
SCHEMBL20200106 0.85 KDM4E (0.60) SLC6A3SLC6A4KDM4ECYP1A2CYP2D6
SCHEMBL269580 0.84 SMN1; SMN2 (0.70) KDM4ECYP1A2CYP2D6CYP2C9CYP2C19
SCHEMBL1515687 0.84 GAA (0.63) SLC6A3SLC6A4KDM4ECYP1A2CYP2D6
SCHEMBL8923988 0.84 SLC6A3 (0.73) SLC6A3SLC6A4KDM4ECYP1A2CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109311813-B Palladium-catalyzed meta-C-H functionalized universal ligands 斯克利普斯研究院 2023-02-28 CN disclosed
EP-1387614-B1 PROCESS FOR PREPARING PURIFIED SHILAJIT COMPOSITION FROM NATIVE SHILAJIT NATREON INC (US) 2005-11-09 EP disclosed
EP-1387614-A4 PROCESS FOR PREPARING PURIFIED SHILAJIT COMPOSITION FROM NATIVE SHILAJIT NATREON INC (US) 2004-09-15 EP disclosed
EP-1435982-A1 DELIVERY SYSTEM FOR PHARMACEUTICAL, NUTRITIONAL AND COSMETIC INGREDIENTS Natreon Inc. (US) 2004-07-14 EP disclosed
EP-1387614-A2 PROCESS FOR PREPARING PURIFIED SHILAJIT COMPOSITION FROM NATIVE SHILAJIT Natreon Inc. (US) 2004-02-11 EP disclosed
WO-2003035094-A1 DELIVERY SYSTEM FOR PHARMACEUTICAL, NUTRITIONAL AND COSMETIC INGREDIENTS NATREON INC. (US) 2003-05-01 WO disclosed
US-20030039662-A1 Process for preparing purified shilajit composition from native shilajit GHOSAL SHIBNATH (IN) 2003-02-27 US disclosed
WO-2002094984-A2 PROCESS FOR PREPARING PURIFIED SHILAJIT COMPOSITION FROM NATIVE SHILAJIT NATREON INC. (US) 2002-11-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030039662-A1 Process for preparing purified shilajit composition from native shilajit Q6ZSR9, CYP26B1, CYP26A1 SLC6A3 4097/4885SLC6A4 3926/4885KDM4E 238/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.